Ginkgolic acid

A phenolic acid.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status

Natural product

Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

Ginkgolic acid is a bioactive phenolic acid (Gerstmeier et al., 2019). It was suggested to act as an irreversible covalent inhibitor of SARS-CoV-2 Papain-like and 3C-like proteases (Chen et al. 2021).

Ginkgolic acid on PubChem


Ginkgolic Acid C15:1


Structure image - Ginkgolic acid


Supporting references

Link Tested on Impact factor Notes Publication date
Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases
3CLpro PapainLpro Small molecule Enzyme assay In vitro In silico
in silico; in vitro enzyme assay; Vero E6 cells; SARS-CoV-2 isolate USA-WA1/2020 5.03

Dose-dependently inhibited SARS-CoV-2 Papain-like protease and 3C-like protease with IC50s of ca. 16.3 μM and 1.79 μM, respectively, in vitro. The compound also blocked SARS-CoV-2 replication with an EC50 of ca. 8.3 μM in Vero E6 cells (at sub-cytotoxic concentrations (CC50 of 27.88 μM)). Based on computational modelling and enzyme assay dynamics, gingkolic acid was suggested to act as an irreversible covalent inhibitor of the cysteine proteases.


AI-suggested references